Vanguard Asset Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.89M Buy
64,982
+8,034
+14% +$213K ﹤0.01% 1577
2026
Q2
$1.02M Buy
56,948
+13,665
+32% +$211K ﹤0.01% 1868
2026
Q1
$602K Buy
+43,283
New +$609K ﹤0.01% 2004

Other funds holding AMLX

Vanguard Asset Management's AMLX Position: Q3 2026 in Review

Vanguard Asset Management increased its Amylyx Pharmaceuticals (AMLX) stake by 14% in Q3 2026, buying an estimated $213K and bringing the position to 64,982 shares worth $1.89M. The position accounts for ﹤0.01% of the portfolio, ranked #1577.

Vanguard Asset Management first reported a position in AMLX in Q1 2026 and has held it in 3 quarters since. 230 funds tracked by Wall St. Rank hold AMLX as of Q3 2026.

  • Vanguard Asset Management held 64,982 shares of Amylyx Pharmaceuticals worth $1.89M as of Q3 2026.
  • Vanguard Asset Management bought 8,034 Amylyx Pharmaceuticals shares in Q3 2026, an estimated $213K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Vanguard Asset Management's portfolio in Q3 2026, its #1577 holding.
  • Vanguard Asset Management first reported a position in Amylyx Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
  • 230 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2026.

Based on Vanguard Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.